Haverford Trust Co Acquires Shares of 218,118 Thermo Fisher Scientific Inc. $TMO

Haverford Trust Co bought a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO) during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 218,118 shares of the medical research company’s stock, valued at approximately $109,356,000. Thermo Fisher Scientific comprises 0.9% of Haverford Trust Co’s portfolio, making the stock its 26th largest position. Haverford Trust Co owned about 0.06% of Thermo Fisher Scientific at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in TMO. Brighton Jones LLC grew its holdings in shares of Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company’s stock worth $2,293,000 after purchasing an additional 988 shares during the last quarter. Revolve Wealth Partners LLC raised its holdings in Thermo Fisher Scientific by 4.2% in the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares during the last quarter. Darwin Wealth Management LLC acquired a new stake in Thermo Fisher Scientific during the 2nd quarter worth approximately $170,000. Raymond James Financial Inc. increased its position in Thermo Fisher Scientific by 7.4% in the 2nd quarter. Raymond James Financial Inc. now owns 778,822 shares of the medical research company’s stock valued at $315,781,000 after acquiring an additional 53,542 shares during the period. Finally, California State Teachers Retirement System raised its stake in shares of Thermo Fisher Scientific by 0.4% during the second quarter. California State Teachers Retirement System now owns 602,031 shares of the medical research company’s stock valued at $244,099,000 after acquiring an additional 2,262 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts recently issued reports on the company. Wolfe Research began coverage on Thermo Fisher Scientific in a research report on Tuesday, June 2nd. They set an “outperform” rating and a $535.00 target price for the company. HSBC lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and lowered their price target for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Wall Street Zen raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, August 1st. Weiss Ratings raised shares of Thermo Fisher Scientific from a “hold (c-)” rating to a “hold (c)” rating in a research note on Tuesday, July 14th. Finally, Wells Fargo & Company cut their price target on shares of Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $619.41.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 4,608 shares of the firm’s stock in a transaction on Friday, August 7th. The stock was sold at an average price of $586.12, for a total value of $2,700,840.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Gianluca Pettiti sold 400 shares of the business’s stock in a transaction on Monday, July 27th. The shares were sold at an average price of $565.00, for a total value of $226,000.00. Following the sale, the chief operating officer owned 24,651 shares in the company, valued at approximately $13,927,815. The trade was a 1.60% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 63,493 shares of company stock worth $37,657,681 over the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $629.02 on Friday. The firm has a market capitalization of $232.58 billion, a P/E ratio of 33.84, a P/E/G ratio of 2.56 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $643.99. The stock has a 50 day moving average price of $542.53 and a two-hundred day moving average price of $509.70. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 EPS for the quarter, beating the consensus estimate of $5.71 by $0.32. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The company had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same quarter in the prior year, the company posted $4.28 earnings per share. The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Tuesday, September 15th will be paid a $0.47 dividend. This represents a $1.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date is Tuesday, September 15th. Thermo Fisher Scientific’s payout ratio is presently 10.11%.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.